Abstract: Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.

Abstract: Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.

Abstract: The present invention concerns polypeptides that possess an enantioselective amidase activity. It also concerns the genetic material required for the expression of these polypeptides as well as a microbiological procedure for their preparation. Finally, this invention concerns the utilization of these polypeptides and of transformed microorganisms for the enantioselective synthesis of acids from racemic amides, and in particular propionic acids, especially (S)-2-aryl-propionamide.

Abstract: Application of N-Methyl-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxide, in the form of a racemic mixture of the 1S,2S and 1R,2R isomers or in the form of the 1R,2R isomer, to the preparation of a medicinal product intended for the treatment of coronary insufficiency.

Abstract: This invention relates to a process for preparing synergistic derivatives of formula (I), in which Y is hydrogen or dimethylamino, from pristinamycin I.sub.A or from virginiamycin, via a Mannich base, followed by elimination of the amine introduced.

Abstract: An apparatus is provided for continuous and regular liberation of active constituents into domestic water supplies. The apparatus comprises a receptacle having a body portion which is impermeable to water and to the active constituent. The receptacle is provided with an aperture closed by a membrane which is permeable to water and to the active constituent. An operculum surrounds the membrane to secure the membrane to the receptacle. The active constituent is provided into the receptacle and is released through the membrane in a controlled manner over an extended period of time. Preferably, the membrane has a mean pore diameter greater than 0.05 microns.

Abstract: A thioformamide derivative of the formula: ##STR1## wherein R represents alkyl, A represents optionally substituted pyrid-3-yl, isoquinolin-4-yl, tetrahydroquinolin-3-yl, quinolin-3-yl, pyridazin-4-yl, pyrimid-5-yl, thiazol-5-yl, thieno[2,3-b]pyridin-5-yl, pyrazin-2-yl, indol-3-yl and thieno[3,2-b]pyridin-6-yl, or phenyl and Y represents a valency bond, methylene or ethylene, R.sup.2 represents hydrogen, optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aryloxyalkyl, aromatic heterocyclylalkyl or aromatic heterocyclyloxyalkyl group or a group ZC(.dbd.O)-- in which Z represents optionally substituted alkyl, aryl, or aromatic heterocyclic, n represents 0 or 1, and when n represents 0, R.sup.1 may represent a hydrogen atom, optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aryloxyalkyl, aromatic heterocyclylalkyl or aromatic heterocyclyloxyalkyl group or a group ZC(.dbd.O)-- or ZSO.sub.2 --, and when n represents 1, R.sup.

Abstract: Terpene derivatives of formula I, their preparation and their use. In formula I, R represents a hydrogen atom or an alkanoyl radical and R' represents a hydrogen atom or an aliphatic hydrocarbon radical.

Abstract: The present invention concerns a DNA sequence coding for a polypeptide with enantioselective amidase activity.

Abstract: Thioformamide derivatives of the formula (I) ##STR1## wherein R represents an alkyl group; A represents either:(1) a phenyl group which is optionally substituted; or(2) heteroaromatic group (e.g. pyrid-3-yl, quinolin-3-yl);Y represents:an ethylene or methylene group or a direct bond; and B represents either:a) a phenyl, pyridyl, furyl or thienyl group, each of which may be optionally substituted, orb) a straight- or branched-chain alkyl, alkenyl, or cycloalkyl group, each of which may be optionally substituted.These compounds may be formulated into pharmaceutical preparations and have utility in the treatment of disorders associated with smooth muscle contraction.

Abstract: The invention provides new inclusion compounds based on imipramine and cyclodextrin and pharmaceutical compositions which can be administered orally and are based on these new inclusion compounds.

Abstract: Acetylenic derivatives of general formula ##STR1## in which R.sub.1 denotes a hydrogen atom or a phenyl radical or a radical of general formula ##STR2## in which R.sub.2 and R.sub.3, which may be identical or different, denote a hydrogen atom or a saturated or unsaturated aliphatic radical, substituted if appropriate, or form together a cycloaliphatic radical, R.sub.4 denotes a hydrogen atom or a saturated or unsaturated aliphatic radical, a hydroxy, alkyloxy, methanesulphonyloxy, benzenesulpnonyloxy or p-toluenesulphonyloxy radical, R.sub.5 denotes a hydrogen atom or a saturated aliphatic radical, R.sub.6 denotes a hydrogen atom or a saturated or unsaturated aliphatic radical are made by reaction of an acetylenic derivative of general formulaR.sub.1 --C.tbd.C--H (III)with an allyl derivative of general formula ##STR3## in the presence of a cuprous salt and an anhydrous organic base. The compounds of formula (I) are useful in organic synthesis, in particular in the preparation of the vitamins A and E.

Abstract: Pharmaceutical compositions are disclosed. They are useful for the treatment of medical conditions associated with the effects of glutamate, comprise as active principle, at least one compound of formula: ##STR1## or a salt thereof, in which either R.sub.1 represents polyfluoroalkoxy, 2,2,2-trifluoroethyl, pentafluoroethyl, tert-butyl, trimethylsilyl or trifluoromethylthio and R.sub.2 and R.sub.3 represent hydrogen,or R.sub.1 represents polyfluoroalkoxy, R.sub.2 represents hydrogen and R.sub.3 represents alkyl, amino, alkoxy, phenyl, phenylalkyl, dimethylamino or dialkylaminoakylthio,or R.sub.1 represents polyfluoroalkoxy, R.sub.2 represents amino and R.sub.3 represents hydrogen, with the exception of 6-trifluoromethoxy-2-benzothiazolamine.

Abstract: Compounds of formula: ##STR1## in which R.sub.1 is (a) a phenyl radical or a substituted phenyl radical, (b) a chain --CH(R.sub.8)--COOR.sub.4, (c) a chain --CH.sub.2 --CO--NR.sub.5 R.sub.6 or (d) a phenylalkyl radical, R.sub.2 is a methylene or ethylene radical or a radical --CH(R.sub.7)--, R.sub.3 is a 1- or 2-naphthyl radical, 2- or 3-indolyl or phenylamino radical in which the phenyl ring is optionally substituted on the understanding that, when R.sub.3 is 1- or 2-naphthyl or 2- or 3-indolyl radical, R.sub.7 cannot represent a benzyl, alkylthioalkyl or phenyl radical, as well as, when R.sub.2 is a radical --CH(R.sub.7)--, their racemates and their stereoisomers, and medicinal products containing them.

Abstract: New porous, unitary freeze-dried pharmaceutical form, of homogeneous appearance, consisting of:a) an inclusion compound comprising:one or optionally more active substances,a predetermined quantity of cyclodextrin,optionally an additive facilitating inclusion,b) at least one substance chosen from:diluents,binders; andc) optionally one or more additives.

Abstract: Terpene derivatives of formula I, their preparation and their use. In formula I, R represents a hydrogen atom or an alkanoyl radical and R' represents a hydrogen atom or an aliphatic hydrocarbon radical.

Abstract: The invention provides a sustained release formulation of ketoprofen comprising granules each of which comprises a core comprising ketoprofen and microcrystalline cellulose and a coating comprising a water-soluble and a water-insoluble cellulose derivative.

Abstract: Process for the preparation of pearls based on a pharmaceutical active substance exhibiting an indefinite crystallization point. The said active substance is mixed in molten form which a pharmaceutical excipient promoting the solidification of the active substance, the melt is forced to pass through a nozzle which is subjected to a vibration, the pearls formed are allowed to fall in a tower countercurrentwise to a gas, and the pearls formed are collected in the bottom of the tower.

Abstract: Application of fluoroqinolone derivatives of general formula (I) is taught, in which R.sub.1 is alkyl (1 to 4C), fluoroethyl, cyclopropyl or difluorophenyl, R.sub.2,R.sub.3 and R.sub.4 are identical or different and represent hydrogen atoms or methyl radicals, X is N or a group .dbd.CR.sub.6 in which R.sub.6 is a hydrogen or fluorine atom, or alternatively R.sub.6 with R.sub.1 and the atoms to which they are attached forms a six-membered heterocycle substituted with a methyl radical and containing an oxygen atom, and R.sub.5 is a hydrogen atom, or represents an amino radical if R.sub.6 is a fluorine atom, as well as of their salts, for obtaining a medicinal product intended for the preventive and/or curative treatment of pneumocystosis.

Abstract: An improved method for preparing citral in liquid phase from prenol and prenal, wherein, in a single reaction enclosure, the prenol and prenal are condensed in the presence of a mineral acid at a concentration of about 5.10.sup.-3 mole for one mole of prenal, 90 to 95% of the acid is neutralized, and once excess prenal and prenol is eliminated, the citral is distilled.